Exploring Health LLC. has successfully completed the re-certification of high-tech enterprise and officially obtained the High-Tech Enterprise Certificate (Certificate No.: GR202544010366) jointly issued by the Department of Science and Technology of Guangdong Province, the Department of Finance of Guangdong Province, and the State Taxation Administration of Guangdong Province, marking that the company's comprehensive strength in technological innovation, R&D investment, and transformation of scientific and technological achievements has been continuously recognized at the national level.
Recently, EH-P002A, a novel wound-healing drug developed by Exploring Health, LLC., has been proven to exert significant effects in promoting cellular migration and wound healing in experiments. More notably, the research team discovered the phenomenon of "cyto-impedance" for the first time through this drug: the drug can effectively promote cellular migration at low concentrations, while at high concentrations, it inhibits cellular migratory ability despite the absence of cytotoxicity.The relevant research findings have been published in the journal Biochemistry and Biophysics Reports.
Our company, Exploring Health CLL, Ltd., has successfully obtained 18 invention patents to date, comprising 10 patents for wound healing promotion, 4 patents for anti-cancer cell metastasis drugs, and 4 patents for anti-COVID-19 drugs. Additionally, we have another 18 patents under review, which include 10 wound healing promotion drugs and 8 anti-cancer cell metastasis drugs.